| AKAM |
Report |
Total revenue |
IN-LINE |
pred ~$1.095B vs. cons $1.093B |
MEDIUM |
| AKAM |
Report |
CIS revenue |
BEAT |
pred ~$104.0M vs. cons $101.7M |
MEDIUM |
| AKAM |
Report |
Non-GAAP diluted EPS |
IN-LINE |
pred ~$1.590 vs. cons $1.582 |
MEDIUM |
| AKAM |
Guide |
Q3 revenue |
UNCHANGED |
guide ~$1.130B vs. cons $1.134B |
LOW |
| AKAM |
Guide |
Q3 non-GAAP diluted EPS |
LOWER |
guide ~$1.675 vs. cons $1.703 |
LOW |
| AKAM |
Guide |
FY26 revenue |
UNCHANGED |
maintain $4.445B-$4.550B vs. cons $4.501B |
MEDIUM |
| AKAM |
Guide |
FY26 CIS growth |
UNCHANGED |
maintain at least 50% CC growth; consensus UNVERIFIED |
LOW |
| AKAM |
Guide |
FY26 CapEx |
UNCHANGED |
maintain ~40%-42% of revenue; consensus UNVERIFIED |
LOW |
| AKAM |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| AKAM |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — lower near-term EPS guidance drives revisions |
LOW |